The clinical observation that heart failure can progress independently of the patient’s
hemodynamic status has focused interest on new, potential mechanisms underlying the
progression of cardiac insufficiency. It has been shown that in both ischemic and non-ischemic
heart failure, endothelial dysfunction and reduced bioavailability of NO can contribute to the
process of left ventricular remodelling. The endothelial dysfunction contributes to increasing peripheral
vascular resistance, limiting blood flow to skeletal muscles, particularly during exercise,
and compromising the regulation of pulmonary blood flow, leading to a flow-perfusion mismatch.
The nitroderivates are a heterogeneous class of compounds that have in common their
pharmacodynamic action, which is mediated through the production of NO.
Isosorbide-2-mononitrate (IS-2-MN) and isosorbide-5-mononitrate (IS-5-MN) are the two main metabolites of isosorbide dinitrate (ISDN) and both act on the smooth muscle cells of vessel walls, causing generalized peripheral vasodilation, which is more marked in the venous system, reduced venous return to the heart and a reduction in peripheral resistance.
The shorter half-life of IS-2-MN compared to that of IS-5-MN allows greater fluctuation of the blood levels of the drug; it can, therefore, be hypothesized that tolerance would develop more slowly.
In the light of the important role of oxidative stress in the progression of heart failure, reduced occupation of the receptors for NO by IS-2-MN could have important implications for the bioavailability of the sulphydryl groups otherwise involved in the denitrification of the organic nitrates. (Heart International 2007; 3: 86-97)
Nitrates, Endothelial dysfunction, Heart failure, Ischemic heart disease
Prof. Oberdan Parodi, CNR Clincal Physiology Institute of Milan, Cardiology Department, Niguarda Cà Granda Hospital, Piazza Ospedale Maggiore, 3, 20162 Milan – Italy, email@example.com
Share this Article
Related Content In Heart Failure
Explaining Sex Differences in Cardiac Resynchronisation Therapy Outcome
European Journal of Arrhythmia & Electrophysiology. 2020;6(1):17-23 DOI: https://doi.org/10.17925/EJAE.2020.6.1.17
Over the past years, several reports have drawn attention to the need to consider sex-specific differences in cardiac resynchronisation therapy (CRT). Most importantly, there is growing concern on the underrepresentation of women in CRT landmark trials which laid the foundation for present guidelines. Patients with symptomatic heart failure, reduced left ventricular ejection fraction (LVEF) ≤35% […]
Quantification of Seasonal Variation in Daily Physical Activity in Individuals with Heart Failure and Implantable Cardioverter Defibrillator/Cardiac Resynchronisation Therapy Devices
Heart International. 2019;13(2):31–7
In individuals with heart failure (HF) who also have implanted cardioverter defibrillators and/or cardiac resynchronisation therapy (ICD/CRT) devices, low daily physical activity (PA) levels lead to increased risk of mortality, poor aerobic capacity and lower health-related quality of life.1 Improving daily PA in these individuals may, therefore, be an important clinical endpoint; however, designing interventional […]
Normalised Heart Rate Variability After Sacubitril/Valsartan
European Journal of Arrhythmia & Electrophysiology. 2019;5(1):60-1 DOI: https://doi.org/10.17925/EJAE.2019.5.1.60
We report the case of a 44-year-old woman with a history of chronic heart failure with reduced ejection fraction (HFrEF) due to ischemic cardiomyopathy (New York Heart Association [NYHA] class II). In 2010, she had a myocardial infarction with thrombotic occlusion of the left anterior descending coronary artery, alleged in the context of an essential thrombocythaemia. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!